This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in New Haven, CT, Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life-transforming drugs, for the treatment of patients with ultra-rare disorders. The company’s complement franchise consists of key growth driver, Soliris, which is approved for the treatment of two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system — paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is also approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA also approved its long-acting C5 complement inhibitor, Ultomiris, for the treatment of adult patients with PNH, to be administered every eight weeks. In October 2019, the FDA approved the use of Ultomiris as a treatment for adult and pediatric (one month of age or older) patients with aHUS to inhibit complement-mediated TMA.
Top Ranked Growth Stocks to Buy for February 10th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, February 10th
How Will Biotech ETFs React to Q4 Earnings?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.
Palatin (PTN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Vyleesi sales are likely to be in focus when Palatin (PTN) releases results for the second quarter of fiscal 2021.
Alexion (ALXN) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) beats earnings and sales estimates for the fourth quarter of 2020.
Merck (MRK) Q4 Earnings & Sales Miss, CEO Frazier Steps Down
by Zacks Equity Research
Merck (MRK) misses Q4 estimates for earnings and sales. CEO Kenneth C. Frazier, to retire.
Alexion Pharmaceuticals (ALXN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Alexion (ALXN) delivered earnings and revenue surprises of 18.40% and 5.70%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Alexion (ALXN)
by Zacks Equity Research
Alexion (ALXN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Top-Ranked Stocks Likely to Beat Earnings Estimates
by Sanghamitra Saha
These top-ranked stocks are likely to beat on bottom line in their next releases.
Abbott's (ABT) Nutrition & Diabetes Care Beat COVID-19 Woes
by Zacks Equity Research
Within pediatric nutrition, Abbott (ABT) registers U.S. sales growth led by increased market share of Similac infant formula brand.
Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion (ALXN) is set to provide updates on revenues and earnings when it releases fourth-quarter 2020 results on Feb 4.
Will Eylea, Dupixent Drive Regeneron's (REGN) Q4 Earnings?
by Zacks Equity Research
Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports fourth-quarter 2020 results.
What's in Store for Innoviva (INVA) This Earnings Season?
by Zacks Equity Research
Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the fourth quarter.
What's in the Cards for Bristol-Myers' (BMY) Q4 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports fourth-quarter 2020 results.
Incyte (INCY) Gets Positive CHMP Opinion for Pemigatinib
by Zacks Equity Research
Incyte's (INCY) pemigatinib gets positive CHMP opinion by the EMA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion.
Dr. Reddy's (RDY) Q3 Earnings Decline Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings decline while sales grow year over year in third-quarter fiscal 2021.
Illumina (ILMN) New Collaboration to Aid Genomics Startups
by Zacks Equity Research
Illumina (ILMN) partners with Sequoia Capital China to set up a genomics-focused startup incubator in China.
5 Promising Price-to-Book Value Stocks to Buy Now
by Kinjel Shah
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high growth prospects.
Zacks.com featured highlights include: Vale, Canadian Solar, Alexion Pharmaceuticals and Affiliated Managers Group
by Zacks Equity Research
Zacks.com featured highlights include: Vale, Canadian Solar, Alexion Pharmaceuticals and Affiliated Managers Group
Will Strong Veklury Sales Aid Gilead's (GILD) Q4 Earnings?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports fourth-quarter 2020 results.
Vertex's (VRTX) IND for Type I Diabetes Drug Gets FDA Clearance
by Zacks Equity Research
Vertex (VRTX) gets FDA clearance for the investigational new drug application of VX-880, for the potential treatment of type I diabetes.
Add These 4 Low P/CF Stocks to Portfolio for Optimum Returns
by Sumit Singh
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Canadian Solar (CSIQ), Alexion Pharmaceuticals (ALXN), Vale S.A. (VALE) and Affiliated Managers Group (AMG) boast low P/CF ratio.
What's in the Cards for HCA Healthcare (HCA) Q4 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) fourth-quarter earnings are likely to have witnessed better patient volumes and improved revenues.
Alexion Pharmaceuticals (ALXN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Encompass Health (EHC) Q4 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
Encompass Health's (EHC) fourth-quarter results gain from improved revenues and lower costs, partly offset by lower volumes in both its segments.
Global Blood's (GBT) MAA for Oxbryta Accepted in Europe
by Zacks Equity Research
Global Blood's (GBT) Marketing Authorization Application for the label expansion of Oxbryta tablets has been accepted by the European Medicines Agency.